Condensed Consolidated Balance Sheets (U.S. Dollars in thousands)

	December 31, 2013	March 31, 2014
	(Audited)	(Unaudited)
Current assets		
Cash and cash equivalents	20,067	22,049
Available-for-sale marketable securities	30,372	41,745
Short-term bank deposits	84,387	102,969
Trade receivables, net	24,911	21,724
Other receivables and prepaid expenses Inventories	6,323 14,190	6,813 14,782
Inventories	180,250	210,082
Long-term investments	180,230	210,002
Available-for-sale marketable securities	113,377	117,346
Long-term bank deposits	37,497	19,389
Severance pay funds	3,319	3,255
Covorance pay range	154,193	139,990
	101,100	100,000
Property and equipment, net	17,523	18,048
Intangible assets, net	5,070	4,589
Other long-term assets	1,629	1,633
Goodwill	30,069	30,069
Total assets	388,734	404,411
Current liabilities		
Trade payables	8,798	7,828
Deferred revenues, other payables and	0,730	7,020
accrued expenses	57,906	64,672
doordod onponess	66,704	72,500
		,000
Long-term liabilities	27,910	28,886
Long-term nabilities	21,310	20,000
Shareholders' equity		
Share capital	611	618
Additional paid-in capital	262,809	267,986
Accumulated other comprehensive	,	,
income	1,733	1,371
Treasury stock, at cost	(25,984)	(25,984)
Retained earnings	54,951	59,034
Total shareholders' equity	294,120	303,025
Tarat Pala Programma and a language of the contract of the con	000 704	404.444
Total liabilities and shareholders' equity	388,734	404,411

Condensed Consolidated Statements of Income (U.S. Dollars in thousands, except share and per share data)

For the Three months ended March 31,

	2013 (Unaudited)	2014 (Unaudited)
Revenues	45,126	51,010
Cost of revenues	<u>8,580</u>	9,446
Gross profit	<u>36,546</u>	<u>41,564</u>
Operating expenses:		
Research and development, net	9,869	10,558
Selling and marketing	19,540	22,412
General and administrative	<u>3,010</u>	5,002
Total operating expenses	<u>32,419</u>	<u>37,972</u>
Operating income	4,127	3,592
Financial income, net	<u>1,115</u>	<u>1,545</u>
Income before taxes on income	5,242	5,137
Taxes on income	<u>(756)</u>	(1,054)
Net income	<u>4,486</u>	<u>4,083</u>
Basic net earnings per share	<u>\$ 0.10</u>	<u>\$ 0.09</u>
Weighted average number of shares used to compute basic net earnings per share	44,615,888	44,941,036
Diluted net earnings per share	<u>\$ 0.10</u>	<u>\$ 0.09</u>
Weighted average number of shares used to compute diluted net earnings per share	46,995,738	46,866,837

Reconciliation of Supplemental Financial Information (U.S. Dollars in thousands, except share and per share data)

For the Three months ended March 31,

	2013	<u>2014</u>
	(Unaudited)	(Unaudited)
GAAP net income	4,486	4,083
Stock-based compensation expenses, included in:		
Cost of revenues	14	10
Research and development	271	259
Selling and marketing	607	594
General and administrative	234	<u>668</u>
	<u>1,126</u>	<u>1,531</u>
Amortization of intangible assets included in:		
Cost of revenues	516	319
Selling and marketing	210	163
Coming and markoning	726	482
Exchange rate differences, net on balance sheet items included in finance income	216	(130)
Acquisition related expenses	<u>485</u>	
Litigation costs	-	<u>1,819</u>
Non-GAAP net income	<u>7,039</u>	<u>7,785</u>
Non-GAAP diluted net earnings per share	<u>\$ 0.15</u>	<u>\$ 0.17</u>
Weighted average number of shares used to compute Non-GAAP diluted net earnings per share	46,995,738	46,866,837